<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01049399</url>
  </required_header>
  <id_info>
    <org_study_id>NP031112-08B02</org_study_id>
    <nct_id>NCT01049399</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy</brief_title>
  <acronym>Tauros</acronym>
  <official_title>A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112, a GSK-3 Inhibitor, Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Noscira SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>i3 Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Noscira SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine wether NP031112 is safe and effective in the
      treatment of mild to moderate Progressive Supranuclear Palsy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change from Baseline between the 2 active study medication groups compared with the placebo group in the Progressive Supranuclear Palsy Rating Scale of Golbe</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of AEs and patients with an incidence rate of ≥ 5% AEs</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline between 2 active study medication groups vs placebo group in Modified Schwab and England Scale</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline between 2 active study medication groups vs placebo group in Timed Up and Go Test (quantitative motor function)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline between 2 active study medication groups vs placebo group in cognitive function(Dementia Rating Scale-2,Frontal Assessment Battery,category and letter verbal fluency)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline between 2 active study medication groups vs placebo group in Starkstein Apathy Scale (behavior)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline between 2 active study medication groups vs placebo group in functional assessments(Unified Parkinson Disease rating Scale part II and European Quality of Life questionnaire)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline between 2 active study medication groups vs placebo group in Clinical Global Impression of Change</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline between 2 active study medication groups vs placebo group in Clinical Global Impression of Severity</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">146</enrollment>
  <condition>Progressive Supranuclear Palsy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>once daily administration of powder for oral suspension.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NP031112 800 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group dosed with 800 mg once daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NP031112 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group treated with 600 mg once daily for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tideglusib</intervention_name>
    <description>800 mg of tideglusib as a powder for oral suspension once daily in fasting conditions for 52 weeks</description>
    <arm_group_label>NP031112 800 mg</arm_group_label>
    <other_name>NP031112</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tideglusib</intervention_name>
    <description>600 mg of tideglusib as a powder for oral suspension, administered once daily in fasting conditions for 52 weeks</description>
    <arm_group_label>NP031112 600 mg</arm_group_label>
    <other_name>NP031112</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>powder for oral suspension administered once daily in fasting conditions for 52 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women with diagnosis of possible or probable PSP according to clinical
             criteria of National Institute of Neurologic Diseases and Stroke - the Society for PSP
             (Appendix 1).

          2. Age of 40 to 85 years (patients over 85 years could be included after previous
             assessment by Investigator and approved by sponsor).

          3. Brain magnetic resonance imaging (MRI) study within 24 months before Baseline visit
             excluding other potential causes of parkinsonism, especially cerebrovascular lesions
             and space occupying lesions.

          4. Mild-to-moderate stage of disease severity according to score of 1 to 4 in Golbe
             Staging System.(Appendix 2)

          5. Female patients must be surgically sterilized; at least 1 year postmenopausal
             (confirmed by follicle-stimulating hormone [FSH] &gt;20 international units [IUs]); using
             adequate birth control (implants, injectables, combined oral contraceptives,
             intrauterine contraceptive device, total sexual abstinence during the study or
             vasectomised partner). Male patients must be willing to use barrier contraception
             (condom) during the study and for 6 months after last treatment administration.

             In European arms of study female patients must be without childbearing potential.

          6. Caregiver (or dedicated nurse) living in same household or interacting with patient
             for &gt;4 hours every day able to assure correct preparation and administration of study
             drug.

          7. Patients living at home or in retirement home not requiring continuous nursing care.

          8. General health status acceptable for participation in 64-week clinical trial.

          9. Ability to swallow 100 mL of water suspension.

         10. Any concomitant medication for PSP must be well-tolerated and unchanged for at least 1
             month prior to Baseline visit and its dose and regimen should be maintained during
             study if there are no clinical reasons to modify it.

         11. Occupational, physical, respiratory, or speech therapy is allowed but it must be
             stable for at least 1 month prior to screening.

         12. Pharmacological treatment of any other chronic condition must be stable and
             well-tolerated for at least 1 month prior to screening. Analgesics, occasional per
             request nonsteroidal anti-inflammatory agents, and treatments for transient or
             emergent conditions are allowed.

         13. Signed informed consent by patient and permitted prior to initiation of any
             study-specific procedure.

        Exclusion Criteria:

          1. Failure to perform screening or baseline examinations.

          2. Hospitalization or change of chronic concomitant medication 1 month prior to or during
             screening period (apart from pre-planned hospitalization for a condition, which did
             not deteriorate since 1 month prior to screening period).

          3. Clinical, laboratory or neuroimaging findings consistent with:

               -  other primary degenerative diseases such as Parkinson's disease; dementia with
                  Lewy bodies; corticobasal degeneration; frontotemporal dementia; multiple system
                  atrophy; parkinsonism-dementia complex of Guam, Kii or Guadeloupe; Alzheimer's
                  disease; amyotrophic lateral sclerosis; Creutzfeldt-Jakob Disease; Huntington's
                  disease; Down's syndrome; etc.

               -  cerebrovascular disease as major, strategic or multilacunar infarcts, or
                  extensive white matter lesions scoring 3 in the Wahlund's scale [Wahlund et al.,
                  2001].

               -  other central nervous system diseases (hydrocephalus, severe head trauma,
                  tumours, subdural haematoma or other relevant space occupying processes, etc.).

               -  epilepsy.

               -  other infectious, metabolic or systemic diseases affecting central nervous system
                  (syphilis, present hypothyroidism, present vitamin B12 or folate deficiency,
                  clinically significant serum electrolyte disturbances, juvenile onset diabetes
                  mellitus, etc.).

          4. A current Diagnostic and Statistical Manual of Mental Disorders Fourth Edition
             (DSM-IV) diagnosis of active major depression, schizophrenia or bipolar disorder.

          5. Clinically significant, advanced or unstable disease that may interfere with primary
             or secondary variable evaluations, may bias clinical or mental assessment or put
             patient at special risk, such as:

               -  chronic liver disease, as indicated by liver function test abnormalities (ALAT,
                  ASAT, bilirubin or GGT out of range) positive serology for Hepatitis C, or other
                  manifestations of liver disease

               -  respiratory insufficiency

               -  renal insufficiency (serum creatinine &gt;2 mg/dL (&gt;150 micromol/L) and creatinine
                  clearance &lt;60 (according to Cockcroft-Gault formula)

               -  heart disease (myocardial infarction, unstable angina, heart failure,
                  cardiomyopathy within 6 months before screening).

               -  bradycardia (heart beat &lt;50/min) or tachycardia (heart beat &gt;95/min)

               -  episodes of unstable or uncontrolled hypertension (systolic pressure &gt;160 mm Hg
                  or diastolic pressure &gt;100 mm Hg) or hypotension (systolic pressure &lt;90 mm Hg or
                  diastolic pressure &lt;45 mm Hg) during 2 months prior to Baseline visit.

               -  atrioventricular block (type II / Mobitz II and type III), congenital long QT
                  syndrome, sinus node dysfunction or prolonged QTcF interval (males &gt;450 msec and
                  females &gt;470 msec using Fridericia's formula: QTc = QT/cube root of RR).

               -  uncontrolled diabetes mellitus.

               -  malignant tumors within last 5 years except skin malignancies (other than
                  melanoma) or indolent prostate cancer.

               -  metastases.

          6. Disability that may prevent the patient from completing all study requirements (e.g.,
             blindness, deafness, and severe language difficulty).

          7. Chronic daily drug intake of:

               -  drugs metabolized by cytochrome P450 (CYP)3A4 with narrow therapeutic window
                  (acenocoumarol, warfarin, and digitoxin)

               -  anticonvulsants indicated for epileptic seizures

               -  systemic anticholinergics with relevant action on central nervous system

               -  acetylcholinesterase inhibitors

               -  neuroleptics except quetiapine, clozapine or other atypical neuroleptics

               -  nootropics such as piracetam, propentofylline, hydergine, vinpocetine, ginkgo
                  biloba, coenzyme Q-10, idebenone and derivatives

               -  centrally active anti-hypertensive drugs such as clonidine, alpha methyl dopa,
                  guanidine, and guanfacine

               -  systemic cortico-steroids or immunosuppressants

               -  systemic nonsteroidal anti-inflammatory agents (except taken as occasional
                  medication per request or acetylsalicylic acid up to 100 mg/day as an
                  antiplatelet agent).

               -  memantine, lithium, valproic acid or other GSK-3 inhibitors within 3 months prior
                  to the Baseline visit.

          8. Suspected or known history of drug abuse or excessive alcohol intake*

          9. Suspected or known allergy to any components of study treatments.

         10. Enrollment in another investigational drug study within 3 months before Baseline
             visit.

         11. Any condition, which in the opinion of Investigator makes patient unsuitable for
             inclusion or likely to be non-compliant.

               -  More than 21 units per week for men and 14 for women; or consumption of more than
                  8 units in a single episode. 1 unit equals approximately 1 glass of wine, 250 ml
                  of beer or 1 shot (25 ml) of spirit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Parkinson's and Movement Disorder Institute</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida 5</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Movement Disorders, University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Medicine and Dentistry, Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson Beelitz</name>
      <address>
        <city>Beelitz-Heilstätten</city>
        <zip>14547</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humboldt Universitat Charite, Campus Virchow, Neurologisch</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Carl-Guslav-Carus, Technische Universitat Dresden, Klinik und Poliklinik fur Neurologie</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Neurologie 0E 7210</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum fur Nervenheilkunde. Klinik fur Neurologie mit Poliklinik.</name>
      <address>
        <city>Marburg</city>
        <zip>35039</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Tuebingen,Eberhard-Karls-Universitat, Universitatsklinikum Neurologie</name>
      <address>
        <city>Tubingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>Barakaldo</city>
        <zip>48902</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundació Ace</name>
      <address>
        <city>Barcelona</city>
        <zip>08014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dpto.neurologia. H. Clinic.</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dpt. Neurologia. Hospital Ramón y Cajal.</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital U. La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta del Hierro</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Donostia</name>
      <address>
        <city>San Sebastian</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mutua Terrassa</name>
      <address>
        <city>Terrasa</city>
        <zip>8221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Departement of Neurology, Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>460009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Walton Centre for Neurology and Neurosurgery NHS Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reta Lila Weston Institute of Neurological Studies,Sara Koe PSP Research Centre</name>
      <address>
        <city>London</city>
        <zip>WC1N 1PJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Ageing Research Unit</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE4 5PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2010</study_first_submitted>
  <study_first_submitted_qc>January 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2010</study_first_posted>
  <last_update_submitted>January 2, 2012</last_update_submitted>
  <last_update_submitted_qc>January 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>October 24, 2012</submitted>
    <returned>November 23, 2012</returned>
    <submitted>November 23, 2012</submitted>
    <returned>December 21, 2012</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

